Ranbaxy Pharmaceuticals Inc. (RPI), a wholly owned subsidiary of Ranbaxy Laboratories Limited (RLL), announced today that RPI has received the prestigious Supplier Award from Wal-Mart, the largest chain store in the U.S., for outstanding performance in the first quarter of 2005. RPI was commended for consistency of products and programs provided to Wal-Mart, which has fulfilled the requests of Wal-Mart customers. "Your company has been outstanding in meeting the criteria for this award, based upon improvement in areas of on-time shipping, performance, innovative programs and partnership," according to Dave Dible, Executive Vice President, Wal-Mart.

"We are extremely pleased with this recognition and look forward to expanding our relationship with Wal-Mart," commented Jim Meehan, Vice President of Sales and Marketing for RPI. Also commenting on the award, Bill Winter, Executive Director of Sales, stated, "This award is something everyone at Ranbaxy has worked very hard to achieve and all members of our team should be very proud of this accomplishment."

Wal-Mart Stores Inc. is a global company with more than 1.3 million associates worldwide and nearly 5,000 stores and wholesale clubs across 10 countries. It operates Wal-Mart Stores, Supercenters, Neighborhood Markets and SAM'S CLUB locations in the United States. Internationally, the company operates in Argentina, Brazil, Canada, China, Germany, Japan, Mexico, Puerto Rico, South Korea and the United Kingdom. The company's securities are listed on the New York and Pacific stock exchanges under the symbol WMT.

Ranbaxy Pharmaceuticals Inc. ("RPI") based in Jacksonville, Florida, is a wholly owned subsidiary of Ranbaxy Laboratories Limited ("RLL"), India's largest pharmaceutical company. RPI is engaged in the sale and distribution of generic and branded prescription products in the U.S. healthcare system.

Ranbaxy Laboratories Limited, India's largest pharmaceutical company, manufactures and markets brand and generic pharmaceuticals and Active Pharmaceutical Ingredients. Ranbaxy's continued focus on R&D has resulted in several approvals in developed markets and significant progress in New Drug Discovery Research. Ranbaxy's foray into Novel Drug Delivery Systems has led to proprietary "platform technologies" resulting in a number of products under development. The Company is selling its products in over 100 countries and has an expanding international portfolio of affiliates, joint ventures and alliances, ground operations in 44 countries and manufacturing operations in 7 countries.

For further information, please contact: